Skip to main content
. Author manuscript; available in PMC: 2021 Oct 11.
Published in final edited form as: J Neurooncol. 2020 Oct 11;149(3):437–445. doi: 10.1007/s11060-020-03627-0

Table 4:

Toxicities at Least Possibly Attributed to Lenalidomide (at any time while on study)

Toxicity Total No. of Patients Grade (by incident)
1 2 3 4
Abdominal pain 2 2
Alanine aminotransferase increased 8 9
Anorexia 4 5
Back pain 1 1
Blood bilirubin increased 2 2 2
Blurred vision 1 1
Bone pain 1 1
Cardiac disorders 1 1
Constipation 16 17 3
Delirium 1 1
Depression 1
Diarrhea 4 4
Dry skin 1 1
Dysgeusia 2 1 1
Fatigue 17 21 4
Gastrointestinal pain 1 1
Headache 7 9
Hemolysis 1 1
Hyperhidrosis 1 1
Hypersomnia 1 1
Hypertension 1 1
Infections and infestations - Gastroenteritis 1 1
Infections and infestations - Staphylococcus aureus 1 1
Insomnia 1 1
Lymphocyte count decreased 15 22 22 12 2
Nausea 4 4
Neutrophil count decreased 8 2 5 6 1
Oral pain 1 1
Pain - L Lower jaw pain 1 1
Palmar-plantar erythrodysesthesia 1 1
Platelet count decreased 17 29 7 9 2
Pruritus 2 2
Rash maculo-papular 3 3
Skin and subcutaneous tissue disorders 3 4 3
Skin hyperpigmentation 1 1
Stomach pain 2 3
Voice alteration 1 1
Vomiting 2 2 1
White blood cell decreased 14 26 14 1